Molecular Neurodegeneration

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	493
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	251
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	251
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	249
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	232
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	215
Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease	206
Regulation of the hippocampal translatome by Apoer2-ICD release	203
Tau interactome and RNA binding proteins in neurodegenerative diseases	178
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	164
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	160
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways	146
Microglia sensing of peripheral signals that bridge the brain and body	130
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	120
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	118
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	115
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	107
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	104
Death-associated protein kinase 1-dependent SENP1 degradation increases tau SUMOylation and leads to cognitive dysfunction in a mouse model for tauopathy	101
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	100
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	100
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	96
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	96
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	92
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	91

HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	88
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	87
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	85
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	85
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	81
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	81
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	80
In Memoriam of Edward H. Koo, MD 1954–2025	77
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	75
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	74
Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer’s disease	71
Combination therapy using GDNF and cell transplant in Parkinson’s disease	69
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	65
Entering the era of precision medicine to treat amyotrophic lateral sclerosis	64
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	64
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	63
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	63
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	63
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	63
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	61
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	57
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	57
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	57
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	56
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	55
Using mass spectrometry to validate mouse models of tauopathy	54
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	54
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes	53
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	53
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	53
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	53
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	53
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	50
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	50
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	49
The endotoxin hypothesis of Alzheimer’s disease	49
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	49
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	47
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	46
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	46
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	45
Diagnostic biomarkers for α-synucleinopathies- state of the art and future developments: a systematic review	45
APOE genotype influences on the brain metabolome of aging mice – role for mitochondrial energetics in mechanisms of resilience in APOE2 genotype	45
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	45
VCP suppresses proteopathic seeding in neurons	44
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases	44
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	44
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	43
Mechanisms of astrocyte aging in reactivity and disease	43
The Hippo signaling pathway as a therapeutic target in Alzheimer’s disease	43

Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	43
Sex specific molecular networks and key drivers of Alzheimer’s disease	42
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	41
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	40
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	40
Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer’s disease	40
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	39
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	39
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	39
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	39
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	39
Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology	38
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	38
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	38
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies	37
Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology	37
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	36
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	36
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	36
Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)	35
The role of inflammasomes in vascular cognitive impairment	35
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	35
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	35
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	35
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	34
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	34
Blood platelet factor 4: the elixir of brain rejuvenation	34
Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion	34
Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities	33
Synaptic dysfunction and glial activation markers throughout aging and early neurodegeneration: a longitudinal CSF biomarker-based study	33
BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides	32
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease	32
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	31
Seeding activity of skin misfolded tau as a biomarker for tauopathies	31
Microglial ferroptotic stress causes non-cell autonomous neuronal death	31
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis	31
Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease	30
Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species	30
Elevated nuclear TDP-43 induces constitutive exon skipping	30
HDGFL2 cryptic protein: a portal to detection and diagnosis in neurodegenerative disease	29
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential	29
Correction: Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	29
Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer’s disease	29
Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity	28
cGAS-STING triggers inflammaging-associated neurodegeneration	28
Mouse models of Anti-Aβ immunotherapies	28
ACSS2-dependent histone acetylation improves cognition in mouse model of Alzheimer’s disease	27
Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease	27
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	27
Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics	27
The integrated stress response in neurodegenerative diseases	27
Pioglitazone modulates metabolic adaptation and peripheral nerve regeneration after injury	26
Aging-associated sensory decline and Alzheimer’s disease	26
Loss of MEF2C function by enhancer mutation leads to neuronal mitochondria dysfunction and motor deficits in mice	26
TREM2 and microglia exosomes: a potential highway for pathological tau	26
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis	26
Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	26
TDP-43 pathology is associated with increased tau burdens and seeding	25
Immune cell metabolic dysfunction in Parkinson’s disease	25
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	25
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	24
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure	24
A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery	24
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells	24
A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	23
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	23
Are oligodendrocytes the missing link in Alzheimer’s disease and related dementia research?	22
Mechanisms of interventions targeting modifiable factors for dementia risk reduction	22
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD	22
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders	22
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains	22
Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models	22
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells	21
Inactivation of NLRP3 inflammasome by dephosphorylation at Serine 658 alleviates glial inflammation in the mouse model of Parkinson’s disease	21
hiPSC-based models to decipher the contribution of human astrocytes to Alzheimer’s disease and potential therapeutics	21
Correction: Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	21
sPLA2-IIA modifies progranulin deficiency phenotypes in mouse models	21
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease	21
Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging	21
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains	21

Does proteopathic tau propagate trans-synaptically in the brain?	20
Single-domain antibody-based protein degrader for synucleinopathies	20
A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological features	20
The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer’s disease	20
Lewy body diseases and the gut	20
The concept of resilience to Alzheimer’s Disease: current definitions and cellular and molecular mechanisms	20
Translation dysregulation in neurodegenerative diseases: a focus on ALS	19
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	19
When the infectious environment meets the AD brain	19
Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis	19
18F-MK-6240 tau PET in patients at-risk for chronic traumatic encephalopathy	19
Alzheimer’s genes in microglia: a risk worth investigating	19
Tau protein profiling in tauopathies: a human brain study	19
To the editor: Response to post-infection cognitive impairments in a cohort of elderly patients with COVID-19, by Wang, Y.J. et al. (2021)	18
Making tracks: microglia and the extracellular matrix	18
Tauopathies: new perspectives and challenges	18
Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia	18
Correction: Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	18
Cellular and molecular mechanisms of pathological tau phosphorylation in traumatic brain injury: implications for chronic traumatic encephalopathy	18
Plasma TDP-43 is a potential biomarker for advanced limbic-predominant age-related TDP-43 encephalopathy neuropathologic change	18
Disparate and shared transcriptomic signatures associated with cortical atrophy in genetic behavioral variant frontotemporal degeneration	18
CD8+ T cells in neurodegeneration: friend or foe?	17
Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques	17
Insights from new in vivo models of TREM2 variants	17
Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease	17
Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease	17
Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology	17
Alzheimer’s disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice	16
Crosstalk of organelles in Parkinson’s disease – MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes	16
Single-cell microglial transcriptomics during demyelination defines a microglial state required for lytic carcass clearance	16
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease	16
Urolithin A promotes p62-dependent lysophagy to prevent acute retinal neurodegeneration	15
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers	15
Simple model systems reveal conserved mechanisms of Alzheimer’s disease and related tauopathies	15
Genetic context modulates aging and degeneration in the murine retina	15
Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	15
Alzheimer’s disease pathogenesis: standing at the crossroad of lipid metabolism and immune response	15
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology	14
Updates on mouse models of Alzheimer’s disease	14
Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease	14
The Alzheimer’s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130	14
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies	14
Midbrain degeneration triggers astrocyte reactivity and tau pathology in experimental Alzheimer’s Disease	14
Altered plasma protein profiles in genetic FTD – a GENFI study	13
Author response to “post-infection cognitive impairments in a cohort of elderly patients with COVID-19”	13
Translational molecular imaging and drug development in Parkinson’s disease	13
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD	12
Regulatory T cells limit age-associated retinal inflammation and neurodegeneration	12
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease	12
Research models to study lewy body dementia	12
TREM2 and sTREM2 in Alzheimer’s disease: from mechanisms to therapies	12
Mitovesicles secreted into the extracellular space of brains with mitochondrial dysfunction impair synaptic plasticity	12
RNA-Targeting CRISPR/CasRx system relieves disease symptoms in Huntington’s disease models	12